Literature DB >> 21245734

Salvinorin A produces cerebrovasodilation through activation of nitric oxide synthase, κ receptor, and adenosine triphosphate-sensitive potassium channel.

Diansan Su1, John Riley, Willis J Kiessling, William M Armstead, Renyu Liu.   

Abstract

BACKGROUND: Salvinorin A is a nonopioid, selective κ opioid-receptor agonist. Despite its high potential for clinical application, its pharmacologic profile is not well known. In the current study, we hypothesized that salvinorin A dilates pial arteries via activation of nitric oxide synthase, adenosine triphosphate-sensitive potassium channels, and opioid receptors.
METHODS: Cerebral artery diameters and cyclic guanosine monophosphate in cortical periarachnoid cerebrospinal fluid were monitored in piglets equipped with closed cranial windows. Observation took place before and after salvinorin A administration in the presence or absence of an opioid antagonist (naloxone), a κ opioid receptor-selective antagonist (norbinaltorphimine), nitric oxide synthase inhibitors (N(G)-nitro-L-arginine and 7-nitroindazole), a dopamine receptor D2 antagonist (sulpiride), and adenosine triphosphate-sensitive potassium and Ca-activated K channel antagonists (glibenclamide and iberiotoxin). The effects of salvinorin A on the constricted cerebral artery induced by hypocarbia and endothelin were investigated. Data were analyzed by repeated measures ANOVA (n = 5) with statistical significance set at a P value of less than 0.05.
RESULTS: Salvinorin A induced immediate but brief vasodilatation that was sustained for 30 min via continual administration every 2 min. Vasodilatation and the associated cyclic guanosine monophosphate elevation in cerebrospinal fluid were abolished by preadministration N(G)-nitro-L-arginine, but not 7-nitroindazole. Although naloxone, norbinaltorphimine, and glibenclamide abolished salvinorin A-induced cerebrovasodilation, this response was unchanged by iberiotoxin and sulpiride. Hypocarbia and endothelin-constricted pial arteries responded similarly to salvinorin A, to the extent observed under resting tone.
CONCLUSIONS: Salvinorin A dilates cerebral arteries via activation of nitric oxide synthase, adenosine triphosphate-sensitive potassium channel, and the κ opioid receptor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245734      PMCID: PMC3387285          DOI: 10.1097/ALN.0b013e318204e029

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  26 in total

1.  Neuroprotective effect of selective kappa opioid receptor agonist is gender specific and linked to reduced neuronal nitric oxide.

Authors:  Emil Zeynalov; Masaaki Nemoto; Patricia D Hurn; Raymond C Koehler; Anish Bhardwaj
Journal:  J Cereb Blood Flow Metab       Date:  2006-03       Impact factor: 6.200

2.  Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats.

Authors:  Christina L Nemeth; Tracie A Paine; Joseph E Rittiner; Cécile Béguin; F Ivy Carroll; Bryan L Roth; Bruce M Cohen; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2010-04-01       Impact factor: 4.530

3.  The role of nitric oxide in opioid-induced pial artery vasodilation.

Authors:  J O Devine; W M Armstead
Journal:  Brain Res       Date:  1995-03-27       Impact factor: 3.252

4.  The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist.

Authors:  G H Rimoy; D M Wright; N K Bhaskar; P C Rubin
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 5.  Salvinorin A: from natural product to human therapeutics.

Authors:  Timothy A Vortherms; Bryan L Roth
Journal:  Mol Interv       Date:  2006-10

Review 6.  Remifentanil update: clinical science and utility.

Authors:  Richard Beers; Enrico Camporesi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

7.  Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans.

Authors:  Jacob M Hooker; Youwen Xu; Wynne Schiffer; Colleen Shea; Pauline Carter; Joanna S Fowler
Journal:  Neuroimage       Date:  2008-03-15       Impact factor: 6.556

Review 8.  Salvinorin A: a novel and highly selective kappa-opioid receptor agonist.

Authors:  Feng Yan; Bryan L Roth
Journal:  Life Sci       Date:  2004-10-15       Impact factor: 5.037

9.  Experimental model of lacunar infarction in the gyrencephalic brain of the miniature pig: neurological assessment and histological, immunohistochemical, and physiological evaluation of dynamic corticospinal tract deformation.

Authors:  Yukitaka Tanaka; Hideaki Imai; Kenjiro Konno; Takaaki Miyagishima; Chisato Kubota; Sandra Puentes; Takeo Aoki; Hidekazu Hata; Kuniaki Takata; Yuhei Yoshimoto; Nobuhito Saito
Journal:  Stroke       Date:  2007-11-29       Impact factor: 7.914

10.  Kir6.2-containing ATP-sensitive potassium channels protect cortical neurons from ischemic/anoxic injury in vitro and in vivo.

Authors:  H-S Sun; Z-P Feng; P A Barber; A M Buchan; R J French
Journal:  Neuroscience       Date:  2006-12-18       Impact factor: 3.590

View more
  12 in total

1.  Salvinorin A pretreatment preserves cerebrovascular autoregulation after brain hypoxic/ischemic injury via extracellular signal-regulated kinase/mitogen-activated protein kinase in piglets.

Authors:  Diansan Su; John Riley; William M Armstead; Renyu Liu
Journal:  Anesth Analg       Date:  2011-11-10       Impact factor: 5.108

2.  The Role of κ Opioid Receptor in Brain Ischemia.

Authors:  Chunhua Chen; Chunhua Xi; Xuan Liang; Jingyuan Ma; Diansan Su; Ted Abel; Renyu Liu
Journal:  Crit Care Med       Date:  2016-12       Impact factor: 7.598

Review 3.  Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.

Authors:  Bronwyn M Kivell; Amy W M Ewald; Thomas E Prisinzano
Journal:  Adv Pharmacol       Date:  2014

4.  Kappa Opioid Receptor Agonist and Brain Ischemia.

Authors:  Chen Chunhua; Xi Chunhua; Sugita Megumi; Liu Renyu
Journal:  Transl Perioper Pain Med       Date:  2014

5.  Herkinorin dilates cerebral vessels via kappa opioid receptor and cyclic adenosine monophosphate (cAMP) in a piglet model.

Authors:  Fang Ji; Zhenhong Wang; Nan Ma; John Riley; William M Armstead; Renyu Liu
Journal:  Brain Res       Date:  2012-10-24       Impact factor: 3.252

6.  Kappa opioid receptors internalization is protective against oxygen-glucose deprivation through β-arrestin activation and Akt-mediated signaling pathway.

Authors:  Jihong Xu; Fang Chen; Shuyan Wang; Nicholas S Akins; Md Imran Hossain; Yi Zhou; Jinxi Huang; Jiafu Ji; Jin Xi; Wenzhen Lin; John Grothusen; Hoang V Le; Renyu Liu
Journal:  Neurochem Int       Date:  2020-04-24       Impact factor: 3.921

7.  Salvinorin A decreases mortality and improves neurological outcome in a neonatal mouse hypoxia model.

Authors:  Chunhua Chen; Xu Cui; Felipe Matsunaga; Jingyuan Ma; Nan Ma; Ted Abel; Renyu Liu
Journal:  Transl Perioper Pain Med       Date:  2014

8.  Salvinorin A: A Mini Review of Physical and Chemical Properties Affecting Its Translation from Research to Clinical Applications in Humans.

Authors:  Edward Orton; Renyu Liu
Journal:  Transl Perioper Pain Med       Date:  2014

9.  Salvinorin A preserves cerebral pial artery autoregulation after forebrain ischemia via the PI3K/AKT/cGMP pathway.

Authors:  H P Dong; W Zhou; X X Ma; Z Z He; Z H Wang
Journal:  Braz J Med Biol Res       Date:  2018-03-15       Impact factor: 2.590

10.  Salvinorin A administration after global cerebral hypoxia/ischemia preserves cerebrovascular autoregulation via kappa opioid receptor in piglets.

Authors:  Zhenhong Wang; Nan Ma; John Riley; William M Armstead; Renyu Liu
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.